Immuron Ltd (IMRN) shareholders
IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Sep 24, 2026Score 4/30
$0.87−0.03 (-3.20%)
Close on Nov 17, 2026Market cap $7.03MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 323M shares
Institutional holders
6
2 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMRN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 43,123 | 0.01% | $45.71K | +29,319 | 0.00% |
| Hrt Financial LP | 20,584 | 0.01% | $21.00K | New | 0.00% |
| Rhumbline Advisers | 7,367 | 0.00% | $7.81K | – | 0.00% |
| Bnp Paribas Arbitrage, Snc | 5,200 | 0.00% | $5.51K | +600 | 0.00% |
| Morgan Stanley | 1,700 | 0.00% | $1.80K | −28,874 | 0.00% |
| UBS Group AG | 363 | 0.00% | $385 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 6 | 0M | 0.0% | 2 / 2 | 1 / 3 | 0M | 0M |
| Q1 2026 | 7 | 0M | 0.0% | 2 / 2 | 3 / 4 | 0M | 0M |
| Q4 2025 | 9 | 0M | 0.1% | 2 / 4 | 2 / 0 | 0M | 0M |
| Q3 2025 | 7 | 0M | 0.0% | 2 / 2 | 1 / 0 | 0M | 0M |
| Q2 2025 | 5 | 0M | 0.0% | 3 / 0 | 0 / 1 | 0M | 0M |
| Q1 2025 | 3 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0.0% | 0 / 0 | 0 / 2 | 0M | 0M |
| Q3 2024 | 3 | 0M | 0.0% | 0 / 1 | 1 / 1 | 0M | 0M |
| Q2 2024 | 4 | 0M | 0.0% | 0 / 2 | 1 / 3 | 0M | 0M |
| Q1 2024 | 7 | 0M | 0.0% | 4 / 0 | 2 / 1 | 0M | 0M |
| Q4 2023 | 4 | 0M | 0.0% | 0 / 1 | 0 / 0 | 0M | 0M |
| Q3 2023 | 4 | 0M | 0.0% | 0 / 0 | 2 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Gerard Brennan | Chairman of the Board, Director | – | – | May 4, 2026 |
| Flavio Palumbo | Chief Commercial Officer | 1,142,909 | 0.35% | May 14, 2026 |
| Steven George Lydeamore | Chief Executive Officer | 3,155,047 | 0.98% | Apr 29, 2026 |
| Aaron James Laurita | Chief Financial Officer | – | – | Apr 29, 2026 |
| Jerry Kanellos | Chief Scientific Officer | 333,000 | 0.10% | Apr 29, 2026 |
| Daniel Jude Pollock | Director | 743,230 | 0.23% | May 14, 2026 |
| Jeannette Anne Joughin | Director | – | – | Apr 29, 2026 |
| Ravi Savarirayan | Director | 877,840 | 0.27% | Apr 29, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.6
At 0M shares a day
Change since last report
-60.6%
From 0M shares
Short volume, 20 days
38.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immuron's stock actually held short. Settlement fails (shares not delivered on time) peaked at 963,733 shares on Sep 8, 2026 over the last 90 days.
See a number that looks wrong?